NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Tak
Post# of 47
Skinvisible, Inc. (OTCQB: SKVI) is working toward developing a transdermal treatment for post-traumatic stress disorder through its patented Invisicare® technology that could address the devastating number of veteran suicides that occur throughout the country. The company’s proposed merger with Quoin Pharmaceuticals would direct Skinvisible’s drug delivery capacity to boost the bioavailability of Quoin’s promising pharmaceuticals. An article discussing this reads: “Skinvisible, through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. … Quoin’s two lead products are targeting crises that result in the death of almost 120 people in the U.S. every day. Data released September 15, 2017, by the U.S. Department of Veteran Affairs (“VA”) show that the risk for suicide was 22 percent higher among veterans when compared to civilians.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer